HDT Bio is a clinical stage private company developing advanced RNA vaccine products to treat and prevent infectious diseases and cancers. Leveraging its proprietary LION™ technology with superior safety, potency, durability, and manufacturing advantages.
HDT Bio is a clinical stage private company developing advanced RNA vaccine products to treat and prevent infectious diseases and cancers. Leveraging its proprietary LION™ technology with superior safety, potency, durability, and manufacturing advantages.
HDT Bio is a clinical stage private company developing advanced RNA vaccine products to treat and prevent infectious diseases and cancers. Leveraging its proprietary LION™ technology with superior safety, potency, durability, and manufacturing advantages.
HDT Bio’s self-replicating RNA (repRNA) vaccines harness the immune system to combat difficult-to-treat conditions and improve patient lives worldwide.
The AMPLIFY vaccine platform — The next generation of RNA vaccines
HDT’s RNA vaccine platform combines its self-amplifying RNA (“repRNA”) and LION™ technology to provide increased potency compared to traditional mRNA vaccines.
Latest News
HDT Bio Publishes Peer-Reviewed Article Describing the Development of an RNA Vaccine to Prevent Infection and Disease Caused by Enterovirus D68
Self-amplifying RNA vaccine, delivered by cationic nanocarrier (LION™) elicits neutralizing antibody responses in mice and nonhuman primates and protects mice from enterovirus D68 (EV-D68) respiratory infection and resulting disease in mice. Findings published in the...
Bioprocess Online Live: Capital, Manufacturing Market Acceptance Of Therapeutic Cancer Vaccines
Click here to view article
Bioprocess Online: Capital, Manufacturing Market Acceptance Of Therapeutic Cancer Vaccines
Click here to view article